3M’s improved Emphaze
On September 5, 3M (MMM) introduced the enhanced version of Emphaze, a hybrid purifier used in biopharmaceutical manufacturing. The new purifier helps reduce cell debris to improve the downstream process. The new Emphaze capsules are sterilization and sanitization compatible, and they can be used across various biopharmaceutical processes.
The new purifier is expected to improve efficiencies and could help reduce costs for biopharmaceutical manufacturers. Himanshu Nivsarkar, Global Marketing Manager of 3M’s Separation and Purification Sciences Division, noted, “With the Emphaze AEX Hybrid Purifier, customers experience benefits in typical monoclonal antibody purification processes, including nominal 30% HCP and greater than 4 log DNA reduction. It has a consistent output turbidity.”
3M (MMM) stock produced a positive performance trend for the week ended September 7, as it gained 0.8% and closed at $212.57. As a result of these gains, 3M stock traded 4.8% above its 100-day moving average price of $202.80. However, on a year-to-date basis, 3M stock has fallen 9.7%.
Among 3M’s peers, General Electric (GE) and Stanley Black & Decker (SWK) have fallen 28.9% and 18.0%, respectively. Honeywell (HON) continued its upward journey and gained ~6.2%. The growing interest among investors in 3M stock pushed its 14-day RSI (relative strength index) to 63, indicating that the stock is neither overbought nor oversold.
Investors can hold 3M indirectly by investing in the SPDR Dow Jones Industrial Average ETF (DIA). DIA invested 5.6% of its portfolio in 3M on September 7.